Beyond treatment intensification: The next questions after CAPITAL.

Rei Ogawa, Junki Mizusawa

原始摘要（英文原文）· Original abstract

The CAPITAL trial shows that SOX improves survival over S-1 after D2 gastrectomy for stage II-III gastric cancer.1 Its broader implication is that further progress will depend on how patients are selected and how systemic therapy is integrated with surgery, not only on the choice of regimen.

读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.
Neoadjuvant FLOT versus SOX chemotherapy in locally advanced gastric cancer: secondary outcomes of a single-centre, open-label, randomised, exploratory phase 2 trial
Combination Treatment of Docetaxel Liposomes and Sonodynamic Therapy With Verteporfin Liposomes in Patients With Cancer: A Report of Three Cases.
Longitudinal changes and deterioration factors of quality of life after gastrectomy for gastric cancer during first postoperative year
Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression.